Cargando…
BRONCHIOLITIS
Bronchiolitis is a common respiratory tract infection usually affecting infants and young children during annual epidemics. It is characterized by wheeze, respiratory distress, and poor feeding. Respiratory syncytial virus (RSV) is the most common cause for bronchiolitis and is amongst the most impo...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149666/ http://dx.doi.org/10.1016/B0-12-370879-6/00048-X |
_version_ | 1783520855899242496 |
---|---|
author | Smyth, R.L. Brearey, S.P. |
author_facet | Smyth, R.L. Brearey, S.P. |
author_sort | Smyth, R.L. |
collection | PubMed |
description | Bronchiolitis is a common respiratory tract infection usually affecting infants and young children during annual epidemics. It is characterized by wheeze, respiratory distress, and poor feeding. Respiratory syncytial virus (RSV) is the most common cause for bronchiolitis and is amongst the most important pathogens causing respiratory infection in infants worldwide. The healthcare burden of bronchiolitis is large, due to large numbers of hospitalized infants and the high risk of nosocomial spread during epidemics. Most children will suffer only mild, short-lived symptoms. A small proportion will need admission to hospital, where treatment is generally supportive until the illness resolves. Some will require ventilatory support for which mortality can be up to 10%. Infants at high risk of severe disease include those born prematurely, those with chronic lung disease, and immunocompromised infants. RSV infects ciliated epithelial cells, causing sloughing of the epithelium, cytokine and inflammatory mediator release, increases in mucus production, and interstitial edema. Clinical manifestations of bronchiolitis are a combined result of viral toxicity and the immune response to infection. Innate immune responses are important to the pathogenesis of bronchiolitis, as severe infection tends to occur after maternal antibody protection has waned and before the infant's adaptive immune responses have matured. Immunoprophylaxis, in the form of intramuscular anti-RSV IgG(1), is effective in reducing rates of hospitalization for high-risk infants. |
format | Online Article Text |
id | pubmed-7149666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71496662020-04-13 BRONCHIOLITIS Smyth, R.L. Brearey, S.P. Encyclopedia of Respiratory Medicine Article Bronchiolitis is a common respiratory tract infection usually affecting infants and young children during annual epidemics. It is characterized by wheeze, respiratory distress, and poor feeding. Respiratory syncytial virus (RSV) is the most common cause for bronchiolitis and is amongst the most important pathogens causing respiratory infection in infants worldwide. The healthcare burden of bronchiolitis is large, due to large numbers of hospitalized infants and the high risk of nosocomial spread during epidemics. Most children will suffer only mild, short-lived symptoms. A small proportion will need admission to hospital, where treatment is generally supportive until the illness resolves. Some will require ventilatory support for which mortality can be up to 10%. Infants at high risk of severe disease include those born prematurely, those with chronic lung disease, and immunocompromised infants. RSV infects ciliated epithelial cells, causing sloughing of the epithelium, cytokine and inflammatory mediator release, increases in mucus production, and interstitial edema. Clinical manifestations of bronchiolitis are a combined result of viral toxicity and the immune response to infection. Innate immune responses are important to the pathogenesis of bronchiolitis, as severe infection tends to occur after maternal antibody protection has waned and before the infant's adaptive immune responses have matured. Immunoprophylaxis, in the form of intramuscular anti-RSV IgG(1), is effective in reducing rates of hospitalization for high-risk infants. 2006 2006-05-13 /pmc/articles/PMC7149666/ http://dx.doi.org/10.1016/B0-12-370879-6/00048-X Text en Copyright © 2006 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Smyth, R.L. Brearey, S.P. BRONCHIOLITIS |
title | BRONCHIOLITIS |
title_full | BRONCHIOLITIS |
title_fullStr | BRONCHIOLITIS |
title_full_unstemmed | BRONCHIOLITIS |
title_short | BRONCHIOLITIS |
title_sort | bronchiolitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149666/ http://dx.doi.org/10.1016/B0-12-370879-6/00048-X |
work_keys_str_mv | AT smythrl bronchiolitis AT breareysp bronchiolitis |